New OTC Rapid COVID-19 Test Approved by FDA
THURSDAY, April 1, 2021 -- An over-the-counter rapid COVID-19 test made by Abbott Laboratories has been approved by the U.S. Food and Drug Administration, the company says.
It said that its BinaxNOW test was granted emergency use authorization by the FDA for nonprescription use at home, The Washington Post reported. "This new indication allows individuals with or without symptoms to have access to this test without a prescription," Abbott said in a statement.
The test provides results in about 15 minutes and "will be simple, even for people who have never tested themselves," according to the company, The Post reported.
Abbott said it expects to begin shipping the tests to major food and drug retailers in the coming weeks and that they may also be available online. The price to consumers is not known, but a company spokeswoman told Reuters that Abbott plans to sell them to retailers for less than $10 each, The Post reported.
The new test could significantly increase Americans' access to COVID-19 testing.
© 2021 HealthDay. All rights reserved.
Posted: April 2021
Further Support and Information on COVID-19
Read this next
TUESDAY, April 20, 2021 -- For U.S. collegiate athletes, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a low prevalence of cardiac...
TUESDAY, April 20, 2021 -- For older persons who are medically unwell and referred for a hospital admission, admission avoidance hospital at home (HAH) with comprehensive...
TUESDAY, April 20, 2021 -- The use of probiotics, omega-3 fatty acids, multivitamins, and vitamin D supplements is associated with a reduction in the risk for testing positive for...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.